A blinded, randomised, placebo-controlled Phase II study to evaluate the safety and efficacy of 12.5 mcg AVAC (TM) (delipidated, deglycolipidated and arabinogalactan depleted derivative of heat-killed Mycobacterium vaccae suspension) in children with moderate-to-severe atopic dermatitis (AD)
Latest Information Update: 16 Jul 2019
Price :
$35 *
At a glance
- Drugs AVAC (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Genesis Research and Development
- 29 Jun 2016 New trial record